Oxford Immunotec Global PLC (OXFD) Financial Statements (2024 and earlier)

Company Profile

Business Address 94C INNOVATION DRIVE
ABINGDON, OX14 4RZ
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2020
MRQ
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 181,270192,84490,33259,11083,71550,165
Cash and cash equivalents 181,270192,84490,33259,11083,71550,165
Restricted cash and investments      200
Receivables 18,32913,65816,98113,2657,0586,823
Inventory, net of allowances, customer advances and progress billings 11,0967,76710,1427,4377,0996,425
Inventory 11,0967,76710,1427,4377,0996,425
Contract with customer, asset, after allowance for credit loss 1,600 
Other undisclosed current assets 3,5862,5113,0272,3903,5922,755
Total current assets: 215,881216,780120,48282,202101,46466,368
Noncurrent Assets
Operating lease, right-of-use asset 7,443
Property, plant and equipment 7,0957,1449,0677,7936,2844,537
Intangible assets, net (including goodwill) 2,5702,54411,81614,839224323
Goodwill 2,4832,4833,9673,8224550
Intangible assets, net (excluding goodwill) 87617,84911,017179273
Restricted cash and investments 10010020020080192
Deferred income tax assets 2,163
Other noncurrent assets   1852,8081830
Deferred tax assets, net1,0522,486   
Other undisclosed noncurrent assets  4,500 16,1701,7822,399
Total noncurrent assets: 19,37115,34023,75441,8108,3887,481
TOTAL ASSETS: 235,252232,120144,236124,012109,85273,849
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 12,81613,69217,97617,48313,74812,786
Employee-related liabilities      3,348
Accounts payable 2,4202,8016,8423,2013,7992,368
Accrued liabilities 10,39610,89111,13414,2829,9497,070
Deferred revenue 19
Debt 98485918479137
Business combination, contingent consideration, liability    882  
Deferred revenue and credits36411,6541,993
Other undisclosed current liabilities  4,2314,342  (3,348)
Total current liabilities: 13,81918,00822,44518,49015,48111,568
Noncurrent Liabilities
Long-term debt and lease obligation 7,74210629,90429,601386454
Long-term debt, excluding current maturities 3210629,90429,601386454
Liabilities, other than long-term debt   3642,9571,2931,218
Other liabilities   364364  
Operating lease, liability 7,710
Business combination, contingent consideration, liability    2,5931,2931,218
Other undisclosed noncurrent liabilities   3,894   
Total noncurrent liabilities: 7,74210634,16232,5581,6791,672
Total liabilities: 21,56118,11456,60751,04817,16013,240
Equity
Equity, attributable to parent 213,691214,00687,62972,96492,69260,609
Common stock 276276269243243192
Additional paid in capital 304,909303,015294,613249,128244,033186,816
Accumulated other comprehensive loss (7,461)(8,523)(5,712)(7,751)(5,277)(4,570)
Accumulated deficit (84,033)(80,762)(201,541)(168,656)(146,307)(121,829)
Total equity: 213,691214,00687,62972,96492,69260,609
TOTAL LIABILITIES AND EQUITY: 235,252232,120144,236124,012109,85273,849

Income Statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 73,71059,753103,08086,07862,78249,505
Revenue, net103,08086,07862,78249,505
Cost of revenue (19,288)(16,826)(46,731)(39,472)(29,544)(24,009)
Cost of goods and services sold (19,288)(16,826)(46,731)(39,472)(29,544)(24,109)
Gross profit: 54,42242,92756,34946,60633,23825,496
Operating expenses (60,545)(63,646)(109,936)(72,583)(57,414)(47,357)
Operating loss: (6,123)(20,719)(53,587)(25,977)(24,176)(21,861)
Nonoperating income (expense) (1,881)(160)(2,059)718(89)(107)
Gain (loss), foreign currency transaction, before tax (1,949)111(1,850)1,364(143)(352)
Other nonoperating income (expense) 68(271)(209)(646)54245
Interest and debt expense  (2,105)    
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 4,247(1,797)24,395(864)(67) 
Loss from continuing operations before equity method investments, income taxes: (3,757)(24,781)(31,251)(26,123)(24,332)(21,968)
Other undisclosed loss from continuing operations before income taxes      (52)
Loss from continuing operations before income taxes: (3,757)(24,781)(31,251)(26,123)(24,332)(22,020)
Income tax expense (benefit) 2,41737,286(1,634)3,774(146)(154)
Income (loss) from continuing operations: (1,340)12,505(32,885)(22,349)(24,478)(22,174)
Income (loss) before gain (loss) on sale of properties:(1,809)120,779(32,885)(22,349)(24,478)(22,174)
Income (loss) from discontinued operations (469)108,274    
Net income (loss) available to common stockholders, diluted: (1,809)120,779(32,885)(22,349)(24,478)(22,174)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss): (1,809)120,779(32,885)(22,349)(24,478)(22,174)
Other comprehensive loss (151)  (2,474)(707)(822)
Comprehensive income (loss): (1,960)120,779(32,885)(24,823)(25,185)(22,996)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 1,213(2,811)2,039   
Comprehensive income (loss), net of tax, attributable to parent: (747)117,968(30,846)(24,823)(25,185)(22,996)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: